PuSH - Publication Server of Helmholtz Zentrum München

Zhang, W.* ; Nowotny, H.* ; Theodoropoulou, M.* ; Simon, J.* ; Hemmer, C.M. ; Bidlingmaier, M.* ; Auer, M.K.* ; Reincke, M.* ; Uhlenhaut, N.H. ; Reisch, N.*

E47 as a novel glucocorticoid-dependent gene mediating lipid metabolism in patients with endogenous glucocorticoid excess.

Front. Endocrin. 14:1249863 (2023)
Publ. Version/Full Text DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
PURPOSE: E47 has been identified as a modulating transcription factor of glucocorticoid receptor target genes, its loss protecting mice from metabolic adverse effects of glucocorticoids. We aimed to analyze the role of E47 in patients with endogenous glucocorticoid excess [Cushing's syndrome (CS)] and its association with disorders of lipid and glucose metabolism. METHODS: This is a prospective cohort study including 120 female patients with CS (ACTH-dependent = 79; ACTH-independent = 41) and 26 healthy female controls. Morning whole blood samples after an overnight fast were used to determine E47 mRNA expression levels in patients with overt CS before and 6-12 months after curative surgery. Expression levels were correlated with the clinical phenotype of the patients. Control subjects underwent ACTH stimulation tests and dexamethasone suppression tests to analyze short-term regulation of E47. RESULTS: E47 gene expression showed significant differences in patient cohorts with overt CS vs. patients in remission (p = 0.0474) and in direct intraindividual comparisons pre- vs. post-surgery (p = 0.0353). ACTH stimulation of controls resulted in a significant decrease of E47 mRNA expression 30 min after i.v. injection compared to baseline measurements. Administration of 1 mg of dexamethasone overnight in controls did not change E47 mRNA expression. E47 gene expression showed a positive correlation with total serum cholesterol (p = 0.0036), low-density lipoprotein cholesterol (p = 0.0157), and waist-arm ratio (p = 0.0138) in patients with CS in remission. CONCLUSION: E47 is a GC-dependent gene that is upregulated in GC excess potentially aiming at reducing metabolic glucocorticoid side effects such as dyslipidemia.
Impact Factor
Scopus SNIP
Altmetric
5.200
0.000
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Acth ; Cushing’s Disease ; Cushing’s Syndrome ; Comorbidity ; Cortisol ; Dyslipidemia ; Transcription Factor 3; Cushings-syndrome; Health; Society; Mechanisms; Receptor; Disease; Burden
Language english
Publication Year 2023
HGF-reported in Year 2023
ISSN (print) / ISBN 1664-2392
e-ISSN 1664-2392
Quellenangaben Volume: 14, Issue: , Pages: , Article Number: 1249863 Supplement: ,
Publisher Frontiers
Publishing Place Lausanne
Reviewing status Peer reviewed
Institute(s) Institute of Diabetes and Endocrinology (IDE)
Institute of Diabetes and Obesity (IDO)
POF-Topic(s) 30202 - Environmental Health
30201 - Metabolic Health
Research field(s)
Helmholtz Diabetes Center
PSP Element(s) G-501900-259
G-502200-001
Grants Deutsche Forschungsgemeinschaft10.13039/501100001659
Scopus ID 85178967237
PubMed ID 38047107
Erfassungsdatum 2023-12-15